CeleCor Therapeutics
Del Mar
About CeleCor Therapeutics
CeleCor Therapeutics develops a RUC-4 novel small molecule inhibitor designed to be the first point of contact treatment for segment elevated myocardial infarction. The molecule inhibitor uses a thrombolytic agent for percutaneous coronary intervention that can be administered subcutaneously by auto-injector, enabling decreased mortality and later development of heart failure.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 1 – 10
- Estimated revenue: $1K – $10K
- Total funding: $46.5M
- Last round: Series Unknown (Mar 2022)
- Website: celecor.com
- Phone: +1 858 777 9750
Industries & Categories
Biotechnology, Medical, Therapeutics
Social Profiles
Canonical: https://fsome.com/organization/celecor-therapeutics-44568 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.